Complete financial analysis of Codexis, Inc. (CDXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codexis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Valens Semiconductor Ltd. WT (VLN-WT) Income Statement Analysis – Financial Results
- PT Arkha Jayanti Persada Tbk (ARKA.JK) Income Statement Analysis – Financial Results
- Brookfield Finance Inc. 4.625% (BAMH) Income Statement Analysis – Financial Results
- Bisichi PLC (BISI.L) Income Statement Analysis – Financial Results
- Bioasis Technologies Inc. (BIOAF) Income Statement Analysis – Financial Results
Codexis, Inc. (CDXS)
About Codexis, Inc.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.14M | 138.59M | 104.75M | 69.06M | 68.46M | 60.59M | 50.02M | 48.84M | 41.80M | 35.31M | 31.92M | 88.30M | 123.87M | 107.10M | 82.91M | 50.48M | 25.33M | 12.13M |
| Cost of Revenue | 12.81M | 38.03M | 22.21M | 13.74M | 15.63M | 12.62M | 14.33M | 9.75M | 6.59M | 9.73M | 14.55M | 30.65M | 41.78M | 27.98M | 16.68M | 13.19M | 8.32M | 1.81M |
| Gross Profit | 57.33M | 100.56M | 82.55M | 55.31M | 52.83M | 47.97M | 35.70M | 39.08M | 35.22M | 25.58M | 17.37M | 57.65M | 82.08M | 79.12M | 66.23M | 37.29M | 17.01M | 10.32M |
| Gross Profit Ratio | 81.74% | 72.56% | 78.80% | 80.10% | 77.17% | 79.17% | 71.36% | 80.03% | 84.25% | 72.45% | 54.41% | 65.29% | 66.27% | 73.87% | 79.88% | 73.87% | 67.16% | 85.11% |
| Research & Development | 58.89M | 80.10M | 55.92M | 44.19M | 33.87M | 29.98M | 29.66M | 22.23M | 20.67M | 22.76M | 31.61M | 56.79M | 61.05M | 52.41M | 54.73M | 45.55M | 35.64M | 17.26M |
| General & Administrative | 52.95M | 51.87M | 49.02M | 34.75M | 31.00M | 28.79M | 28.31M | 24.92M | 22.02M | 21.64M | 26.41M | 30.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 300.00K | 300.00K | 300.00K | 300.00K | 500.00K | 500.00K | 700.00K | 500.00K | 300.00K | 300.00K | 500.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.25M | 52.17M | 49.32M | 35.05M | 31.50M | 29.29M | 29.01M | 25.42M | 22.32M | 21.94M | 26.91M | 31.38M | 36.94M | 33.84M | 29.87M | 35.71M | 19.71M | 11.88M |
| Other Expenses | 13.27M | 124.00K | 1.15M | -156.00K | -656.00K | -291.00K | -92.00K | -94.00K | -168.00K | -234.00K | 24.74M | -326.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.40M | 132.27M | 105.24M | 79.23M | 65.38M | 59.27M | 58.67M | 47.65M | 42.99M | 44.69M | 58.51M | 88.16M | 97.99M | 86.25M | 84.60M | 81.26M | 55.36M | 29.14M |
| Cost & Expenses | 138.21M | 170.30M | 127.45M | 92.98M | 81.01M | 71.89M | 72.99M | 57.40M | 49.57M | 54.42M | 73.07M | 118.81M | 139.77M | 114.23M | 101.27M | 94.45M | 63.68M | 30.94M |
| Interest Income | 4.17M | 1.44M | 459.00K | 405.00K | 1.29M | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 60.00K | 252.00K | 273.00K | 166.00K | 180.00K | 1.54M | 1.49M | 742.00K |
| Interest Expense | 0.00 | 1.44M | 0.00 | 0.00 | 0.00 | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 304.00K | 274.00K | 675.00K | 1.20M | 2.04M | 2.37M | 2.53M | 724.00K |
| Depreciation & Amortization | 9.92M | 10.25M | 5.95M | 4.55M | 4.77M | 1.15M | 1.04M | 4.55M | 5.41M | 6.69M | 10.32M | 12.42M | 11.47M | 8.31M | 6.13M | 4.56M | 2.88M | 2.39M |
| EBITDA | -49.28M | -23.07M | -16.75M | -19.37M | -7.99M | -10.15M | -21.93M | -4.02M | -2.36M | -12.64M | -31.07M | -18.17M | -4.84M | 681.00K | -12.06M | -37.87M | -35.67M | -15.69M |
| EBITDA Ratio | -70.26% | -20.60% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.71% | -34.56% | -3.36% | 1.26% | -14.54% | -75.03% | -134.09% | -129.36% |
| Operating Income | -68.07M | -31.71M | -22.70M | -23.92M | -12.55M | -11.30M | -22.97M | -8.56M | -7.77M | -19.11M | -41.15M | -30.51M | -15.91M | -7.12M | -18.37M | -43.97M | -38.34M | -18.82M |
| Operating Income Ratio | -97.04% | -22.88% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.90% | -34.56% | -12.84% | -6.65% | -22.15% | -87.11% | -151.36% | -155.16% |
| Total Other Income/Expenses | -8.10M | 1.57M | 1.61M | 249.00K | 631.00K | 380.00K | 55.00K | -34.00K | -149.00K | -216.00K | -244.00K | -74.00K | -402.00K | -1.03M | -1.86M | -827.00K | -1.04M | 18.00K |
| Income Before Tax | -76.17M | -33.32M | -21.09M | -23.67M | -11.92M | -10.92M | -22.92M | -8.60M | -7.92M | -19.33M | -41.39M | -30.59M | -16.31M | -8.16M | -20.22M | -44.80M | -39.39M | -18.80M |
| Income Before Tax Ratio | -108.59% | -24.04% | -20.13% | -34.28% | -17.41% | -18.01% | -45.81% | -17.61% | -18.94% | -54.74% | -129.66% | -34.64% | -13.17% | -7.62% | -24.39% | -88.75% | -155.47% | -155.01% |
| Income Tax Expense | 69.00K | 276.00K | 189.00K | 339.00K | 17.00K | -37.00K | 81.00K | -40.00K | -338.00K | -256.00K | -87.00K | 270.00K | 241.00K | 384.00K | 66.00K | 327.00K | -408.00K | -127.00K |
| Net Income | -76.24M | -33.59M | -21.28M | -24.01M | -11.94M | -10.88M | -23.00M | -8.56M | -7.58M | -19.07M | -41.30M | -30.86M | -16.55M | -8.54M | -20.29M | -45.13M | -38.98M | -18.67M |
| Net Income Ratio | -108.69% | -24.24% | -20.31% | -34.77% | -17.43% | -17.95% | -45.97% | -17.52% | -18.13% | -54.01% | -129.39% | -34.95% | -13.36% | -7.97% | -24.47% | -89.40% | -153.86% | -153.96% |
| EPS | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| EPS Diluted | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| Weighted Avg Shares Out | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
| Weighted Avg Shares Out (Dil) | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2022 Results - Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Stephen Dilly - Board...
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis Shares Slide On CEO Transition
Codexis, Inc. (NASDAQ: CDXS) has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9, 2022. After ten years of leading the transformation and growth of Codexis, the current President and CEO, John Nicols, will step...
Why Codexis Shares Are Slumping Today
Codexis Inc (NASDAQ: CDXS) expects Q2 sales of approximately $38 million and FY22 sales of 135 million to $141 million, below the propr expectation of $152 million - $158 million. FY22 product revenues are expected to be $112 million - $118 million, consistent with...
Codexis stock drops as forecast comes in below Street estimate
Codexis Inc. CDXS shares fell in the extended session Thursday after the biotech company lowered its revenue forecast for the year and said that sales from Pfizer Inc. PFE would come in at the low end of an expected range....
Codexis, Inc. (CDXS) CEO John Nicols on Q1 2022 Results - Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Nicols – President and Chief Executive Officer Ross Taylor – Senior Vice President and Chief Financial Officer Brendan Strong – Investor Relations,...
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentations highlighting three of the Company's gene therapy programs using directed evolution...
After Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS)
Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the...
Codexis to Report First Quarter 2022 Financial Results on May 5
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the first quarter of 2022 on...
Codexis and seqWell Announce Strategic Investment and Partnership Initiation
REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell’s genomics workflow solutions. Codexis, a leading enzyme engineering company enabling the...
Source: https://incomestatements.info
Category: Stock Reports